Home › Trial NCT04382352
B002 in Patients With HER2-positive Breast Cancer
- Trial IDNCT04382352
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorShanghai Pharmaceuticals Holding Co., Ltd
- Enrollment23
- Start date2019-05-28
- ConditionsRecurrent Breast Cancer · Metastatic Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Human verification coming soon — the enriched analysis will be viewable here.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.